Hemostemix Stock Price, News & Analysis

Hemostemix (OTCQB: HMTXF) highlighted a remarkable patient success story of Howie Lindeman, who has gained over 17 years of life following a VesCell™ (ACP-01) treatment in 2008. Howie, a six-time Grammy Award-winning producer, received the autologous stem cell therapy for ischemic cardiomyopathy, resulting in his ejection fraction nearly doubling from the low 20% range to the 40% range.

The company's VesCell™ therapy, now authorized under Florida's SB 1768 for patients with life-threatening conditions, has treated 498 patients across seven clinical studies, with results documented in 11 peer-reviewed publications. Studies have shown up to a 47.1% increase in ejection fraction in dilated cardiomyopathy patients.

Hemostemix (OTCQB: HMTXF) has partnered with MedLoanFinancing to provide financing options for its VesCell™ (ACP-01) stem cell therapy treatments in Florida. The financing allows patients to access up to $50,000 in credit through monthly payment plans, making the treatment more accessible under Florida's SB 1768 law.

The company is presenting significant clinical trial results to medical facilities in Naples and Boca Raton. The trials showed that ulcer size in treated patients decreased from 1.46 cm² to 0.48 mm² within 3 months (p = 0.01), while the placebo group showed no significant improvement (p < 0.54).

Hemostemix (OTCQB: HMTXF) has launched its face-to-face sales program in Florida for its VesCell™ (ACP-01) autologous stem cell therapy. The initiative focuses on Miami, Naples, and Tampa, leveraging Florida's SB 1768 law that allows advanced cell therapies for patients with life-threatening conditions who have exhausted standard treatments.

The company has treated 498 patients across seven clinical studies involving 318 subjects, resulting in 11 peer-reviewed publications. Clinical results show significant improvements in treating conditions like peripheral arterial disease, with ulcer size reduction from 1.46 cm² to 0.48 mm² in treated groups. The therapy has also demonstrated positive outcomes in treating chronic stable angina and improving cardiac function.

Hemostemix (OTCQB: HMTXF) has announced an enhanced investor awareness and social media strategy for its autologous stem cell therapy platform VesCell™. The company has reported $1,143,983 in Therapy Convertible Debenture sales year-to-date and is expanding its presence in Florida.

The company's treatment platform has demonstrated significant clinical results, including up to 47.1% increase in ejection fraction in cardiomyopathy patients and a 99% reduction in ulcerating wounds in Phase II CLTI trials. With 498 treatments completed and 11 peer-reviewed publications, Hemostemix is leveraging multiple social media platforms to reach both investors and potential patients suffering from various cardiovascular conditions.

Hemostemix (OTCQB: HMTXF), a leading autologous stem cell therapy company, has announced its AI strategy implementation plan through an upcoming webinar on August 21, 2025. The company's Chief Commercialization Officer, Croom Lawrence, will present their comprehensive approach to integrating AI across patient engagement, clinical research, and corporate operations.

The strategy encompasses three main areas: Patient Care Innovations including HIPAA-compliant precision medicine diagnostics and cognitive decline screening; Clinical & Scientific Advancement featuring AI-powered research and predictive analytics; and Operational Efficiency with automated workflows projected to reduce overhead by up to 20%.

Hemostemix (OTCQB: HMTXF) has announced a significant expansion of its marketing team to drive sales of its VesCell™ (ACP-01) therapy in Florida. The company has appointed three key executives: Croom Lawrence as Chief Commercial Officer, bringing 25+ years of biotech launch experience, Sana Farooqui as Fractional Chief Marketing Officer, and Bob Branch as Fractional VP of Digital Marketing & Media.

Under Florida's Right-to-Try statute, VesCell™ can now be offered to qualifying patients for treating conditions including PAD, CLTI, angina, and various cardiomyopathies. The therapy has shown promising results in multiple clinical trials, demonstrating improved circulation, reduced amputation needs, and enhanced cardiac function.

Hemostemix (OTCQB: HMTXF) has announced a new partnership with Empire Market Ventures (EMV), a New York City-based consulting firm specializing in investor market awareness and strategic communications. EMV will provide market awareness services to enhance Hemostemix's visibility in the capital markets.

The partnership aims to leverage EMV's expertise in digital media and market intelligence to develop comprehensive investor engagement strategies. EMV will operate independently and at arm's length from Hemostemix to ensure unbiased guidance and regulatory compliance.

Hemostemix (OTCQB: HMTXF) has increased its previously closed non-brokered private placement from $2,969,600 to $3,000,000 through the issuance of 3,000,000 additional units at $0.10 per unit. Each unit comprises one common share and one warrant exercisable at $0.15 for 24 months.

The company paid $100,032 in finder's fees and issued 1,000,320 finder's options. The proceeds will be used to repay CD#1 at a 50% discount ($1,250,000) and for general working capital. The offering constitutes a related party transaction, with directors Peter Lacey and Loran Swanberg participating. Following the offering, Mr. Lacey's ownership increased to 13.40% of outstanding shares (non-diluted) and 15.6% on a partially diluted basis.

Hemostemix (OTCQB: HMTXF) has announced groundbreaking research published in Cells regarding how its ACP-01 and NCP-01 cell therapies could potentially improve brain-computer interface (BCI) longevity and performance.

The research demonstrates how these autologous blood-derived cell precursors could address key limitations of BCIs, which currently fail within 6 months to 1 year. ACP-01 produces signals that suppress inflammation and support blood vessel growth, while NCP-01 promotes neural plasticity and new synaptic connections.

The company sees potential for licensing opportunities with BCI technology companies to combine their stem-cell therapy with cutting-edge neural interfaces, aiming to extend implant longevity from months to potentially a lifetime while improving signal fidelity and learning capabilities.